NCT02699840View on ClinicalTrials.gov

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 25, 2016

Study Completion Date

July 25, 2016

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

No vaccine will be provided as part of this study

BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

No vaccine will be provided as part of this study

BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

No vaccine will be provided as part of this study

Trial Locations (1)

Unknown

Moscow

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02699840 - Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation | Biotech Hunter | Biotech Hunter